PTGX
Protagonist Therapeutics Inc

3,355
Mkt Cap
$4.89B
Volume
725,894.00
52W High
$93.25
52W Low
$33.31
PE Ratio
110.33
PTGX Fundamentals
Price
$78.50
Prev Close
$77.85
Open
$77.53
50D MA
$66.57
Beta
0.58
Avg. Volume
1.18M
EPS (Annual)
$4.23
P/B
7.31
Rev/Employee
$3.45M
Loading...
Loading...
News
all
press releases
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.
Stocktwits·19d ago
News Placeholder
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
The research firm said its higher target better reflects the value of Protagonist’s key drug assets, Rusfertide and Icotrokinra.
Stocktwits·20d ago
News Placeholder
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
Zacks·20d ago
News Placeholder
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the...
CNBC Television-YouTube·23d ago
News Placeholder
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Zacks·2mo ago
News Placeholder
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Zacks·3mo ago
News Placeholder
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Zacks·4mo ago

Latest PTGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.